Medicine and Dentistry
Neoplasm
100%
Malignant Peripheral Nerve Sheath Tumor
76%
MEK Inhibitor
42%
Pediatrics
42%
Sarcoma
40%
Neurofibromatosis Type I
36%
Plexiform Neurofibroma
30%
Oncology
25%
Overall Survival
24%
Metastatic Carcinoma
23%
Wilms' Tumor
22%
Ewing Sarcoma
21%
Ganglioglioma
20%
Soft Tissue Sarcoma
20%
Signal Transduction
18%
Xenograft
18%
Nerve Sheath Tumor
17%
Malignant Neoplasm
16%
Disease Course
16%
Childhood Cancer
16%
Phosphoprotein
14%
Gene Fusion
14%
Adenoma
14%
Desmoplastic Small Round Cell Tumor
14%
Brain Tumor
14%
Gene Mutation
14%
Protein Tyrosine Kinase
12%
Disease
12%
Cancer
12%
Carcinogenesis
12%
Tumor Progression
12%
Adolescent
12%
Clinical Trial
12%
Combination Therapy
11%
Mitogen-Activated Protein Kinase
11%
Targeted Therapy
11%
Peripheral Nerve
11%
Recurrent Disease
11%
Progression Free Survival
10%
Aneuploidy
10%
Lung Cancer
10%
Epidermal Growth Factor Receptor
10%
Chromosome 8
10%
Rhabdomyosarcoma
9%
Dabrafenib
9%
Pelvis
9%
Lung Metastasis
9%
Patient Referral
9%
Systemic Therapy
9%
Tyrosine-Kinase Inhibitor
9%
Keyphrases
Malignant Peripheral Nerve Sheath Tumor (MPNST)
47%
MEK Inhibitor (MEKi)
36%
Pediatric
34%
Tumor
31%
Older Adults
27%
Neurofibromatosis Type I
25%
Neurofibromatosis Type 1 (NF-1)
25%
Rhabdomyosarcoma
22%
Overall Survival
22%
Solid Tumors
22%
Wilms Tumor
22%
BRAF Inhibitor (BRAFi)
21%
BRAF V600E
20%
Young Adult Patients
17%
Soft Tissue Sarcoma
17%
V600E-BRAF
16%
Melanoma
16%
Neoplasms
15%
Farnesylation
14%
Metanephric Adenoma
14%
RND1
14%
Novel Therapeutics
14%
Dabrafenib
14%
BRAF V600E mutation
14%
Chemotherapy
13%
Clinical Course
13%
Glioma
13%
BRAF mutation
12%
Sarcoma
12%
Genetic Modification
12%
Highly Aggressive
12%
Oncogene
12%
Mutant BRAF
11%
ERK Kinase
11%
Ewing Sarcoma
10%
Pediatric Cancer Patients
9%
Clinical Outcomes
9%
PLX4032
9%
Cancer Predisposition Syndrome
9%
ERK Pathway
9%
Progression-free Survival
9%
Pediatric Oncology
9%
Complete Response
9%
Preadolescent children
8%
Recommended Phase 2 Dose
8%
Bone Tissue
8%
Retrospective Analysis
8%
Kinase Inhibition
8%
Metastatic Disease
8%
Tumor Suppressor
7%
Biochemistry, Genetics and Molecular Biology
MEK Inhibitor
42%
Genetics
40%
Mitogen-Activated Protein Kinase
32%
Epidermal Growth Factor Receptor
31%
Phosphotransferase
27%
Kinase
27%
Oncogene
25%
Signal Transduction
17%
Extracellular Signal-Regulated Kinases
15%
Gene Mutation
15%
Mitogen-Activated Protein Kinase Kinase
14%
HRAS
14%
Telomere
14%
Antineoplastic Activity
14%
Carcinogenesis
14%
Tumor Progression
13%
Wild Type
13%
Cancer Cell
13%
KRAS
11%
Receptor Tyrosine Kinase
11%
Colon
11%
Dabrafenib
11%
Cell Cycle
11%
Exon
10%
Small Molecule
10%
Proteomics
10%
Cell Mutant
10%
Tumor Suppressor Protein
9%
Clinical Trial
9%
RNA Sequence
9%
Adaptive Response
9%
Physiological Feedback
9%
Transcriptomics
9%
WT1
8%
Chromosome 8
8%
Drug Response
8%
Drug Resistance
7%
Alpha Thalassemia/Mental Retardation X-Linked
7%
Drive
7%
Molecular Biology
7%
PLK1
7%
Inhibitor of Apoptosis
7%
P16
7%
Gene Fusion
7%
Product Inhibition
7%
Cyclin D1
7%
Oncogene C Myc
7%
Phosphoprotein
7%
Antiproliferative Activity
7%
Myc Protein
7%
